Genmab A (GMAB) EBITDA (2018 - 2026)

Genmab A has reported EBITDA for 6 years, with the latest figure at -$106.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 150.96% year-over-year to -$106.0 million; the trailing twelve-month figure through Mar 2026 stood at $848.0 million (down 5.25% YoY), and the FY2025 full-year result was $1.1 billion, up 9.57% from the prior year.
• EBITDA for Q1 2026 stood at -$106.0 million, down from $407.0 million in the prior quarter.
• The five-year high for EBITDA was $407.0 million in Q3 2025, with the low at -$106.0 million in Q1 2026.
• Historically, EBITDA has averaged $219.3 million across 3 years, with a median of $208.0 million in 2025.
• Annual changes were most pronounced in 2025 — EBITDA surged 95.95% — and 2026, when it tumbled 150.96%.
• Genmab A's EBITDA stood at $315.0 million in 2024, then climbed by 29.21% to $407.0 million in 2025, then sank by 126.04% to -$106.0 million in 2026.
• The last three EBITDA figures came in at -$106.0 million (Q1 2026), $407.0 million (Q3 2025), and $339.0 million (Q2 2025), per Business Quant data.